Evidence map›Paper›PMID 30551619›Full record

ReviewInternational journal of molecular sciences2018

Lymphatic Vascular Structures: A New Aspect in Proliferative Diabetic Retinopathy.

Erika Gucciardo, Sirpa Loukovaara, Petri Salven, Kaisa Lehti

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 26 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Novel therapies for proliferative retinopathies.Therapeutic advances in chronic disease · 2022
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 2 countries.

Erika GucciardoResearch Programs Unit, Genome-Scale Biology, Biomedicum Helsinki, University of Helsinki, FI-00014 Helsinki, Finland. erika.gucciardo@helsinki.fi.ORCID 0000-0003-4481-8798
Sirpa LoukovaaraUnit of Vitreoretinal Surgery, Ophthalmology, University of Helsinki and Helsinki University Hospital, FI-00014 Helsinki, Finland. sirpa.loukovaara@hus.fi.
Petri SalvenDepartment of Pathology, University of Helsinki and Helsinki University Hospital, FI-00014 Helsinki, Finland. petri.salven@helsinki.fi.
Kaisa LehtiResearch Programs Unit, Genome-Scale Biology, Biomedicum Helsinki, University of Helsinki, FI-00014 Helsinki, Finland. kaisa.lehti@ki.se.
University of Helsinki · FI

Funding

Academy of Finland NADiabetes Research Foundation NADoctoral Programme in Biomedicine NAEye and Tissue Bank Foundation NAFinnish Cancer Institute NAHelsingin Yliopisto NAHUCH Clinical Research Grants TYH2016230HUCH Clinical Research Grants TYH2018127K. Albin Johanssons Stiftelse NAKarolinska Institutet NAMary and Georg C. Ehrnrooth Foundation NASigrid Juséliuksen Säätiö NA
6 · The paper itself

Abstract

Diabetic retinopathy (DR) is the most common diabetic microvascular complication and major cause of blindness in working-age adults. According to the level of microvascular degeneration and ischemic damage, DR is classified into non-proliferative DR (NPDR), and end-stage, proliferative DR (PDR). Despite advances in the disease etiology and pathogenesis, molecular understanding of end-stage PDR, characterized by ischemia- and inflammation-associated neovascularization and fibrosis, remains incomplete due to the limited availability of ideal clinical samples and experimental research models. Since a great portion of patients do not benefit from current treatments, improved therapies are essential. DR is known to be a complex and multifactorial disease featuring the interplay of microvascular, neurodegenerative, metabolic, genetic/epigenetic, immunological, and inflammation-related factors. Particularly, deeper knowledge on the mechanisms and pathophysiology of most advanced PDR is critical. Lymphatic-like vessel formation coupled with abnormal endothelial differentiation and progenitor cell involvement in the neovascularization associated with PDR are novel recent findings which hold potential for improved DR treatment. Understanding the underlying mechanisms of PDR pathogenesis is therefore crucial. To this goal, multidisciplinary approaches and new ex vivo models have been developed for a more comprehensive molecular, cellular and tissue-level understanding of the disease. This is the first step to gain the needed information on how PDR can be better evaluated, stratified, and treated.

Indexed as

Cell DifferentiationDiabetic RetinopathyEndothelial Progenitor CellsEpigenesis, GeneticFemaleGenetic Predisposition to DiseaseHumansMaleMetabolic Networks and PathwaysNeovascularization, Pathologicangiogenesisendothelial progenitor celllymphangiogenesislymphaticsLyve1ocularproliferative diabetic retinopathy

Identifiers

PMID30551619
PMCPMC6321212
OpenAlexW2904157569

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.